Amgen (AMGN) said Friday that a phase 3 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung cancer met its primary endpoint at a planned interim analysis.
The biopharmaceutical company said the data show that Imdelltra demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.
Amgen said the randomized open-label clinical trial is evaluating the efficacy and safety of Imdelltra as a treatment for patients with SCLC who progressed on or after a single line of platinum-based chemotherapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.